Zhejiang Jianfeng Group (SHA:600668) unit Jianfeng Pharmaceutical obtained marketing and manufacturing approval from China's drug regulator for metformin and empagliflozin tablets.
The combination therapy is used for type 2 diabetes, according to a Tuesday filing with the Shanghai bourse.
The registration is valid for 24 months.
Shares of the pharmaceutical company closed 2% lower Tuesday.
Farglory Land Development (TPE:5522) approved a NT$3.8 billion construction contract for a project in Tainan's East District, according to a Monday Taiwan Exchange filing.Shares slid over 1% in Tuesday's late morning trade.The contract involves a joint venture to develop land in the Dongguang Section, with work to be carried out by its unit, Farglory Construction.The project is expected to support future revenue growth upon completion.The company did not disclose a timeline for the project.
China Northern Rare Earth (SHA:600111) expects attributable profit to jump 109% to 118% to between 900 million yuan and 940 million yuan in the first quarter from 430.6 million yuan in the year-ago period, according to a Tuesday filing with the Shanghai bourse.The upbeat forecast is attributable to a price increase in rare earths, as well as cost reduction and risk control, the filing said.Shares fell 4% during the midday break.
Sinomach Precision Industry's (SHE:002046) net profit attributable to shareholders in 2025 slipped 7% to 260.3 million yuan from 279.8 million yuan a year earlier, according to a Shenzhen bourse filing on Tuesday.Earnings per share fell 8% year on year to 0.49 yuan from 0.53 yuan.Operating revenue jumped 14% to 3.02 billion yuan from 2.66 billion yuan in the previous year.The Chinese industrial equipment manufacturer's shares jumped 5% during the morning trade.